Compare Stocks: LOGC, NBTX, SRPT, and AUPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$16.29 -1.2%	$15.98	$10.34 ▼ $19.25	$2.17B	1.42	1.16 million shs	630,567 shs
LOGC LogicBio Therapeutics	$12.84 +1.7%	$9.88	$7.05 ▼ $13.25	$587.19M	2.02	160,361 shs	54,304 shs
NBTX Nanobiotix	$41.23 -8.7%	$39.24	$8.03 ▼ $57.14	$2.09B	0.78	175,373 shs	164,856 shs
SRPT Sarepta Therapeutics	$20.86 -3.4%	$17.73	$14.68 ▼ $25.32	$2.20B	0.24	3.01 million shs	3.61 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	0.00%	-2.16%	+8.60%	+6.26%	+34.52%
LOGC LogicBio Therapeutics	0.00%	+13.23%	+33.75%	+42.98%	+72.35%
NBTX Nanobiotix	0.00%	-5.33%	+2.69%	+2.05%	+359.90%
SRPT Sarepta Therapeutics	0.00%	+11.02%	+34.06%	+16.73%	+15.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$16.29 -1.2%	$15.98	$10.34 ▼ $19.25	$2.17B	1.42	1.16 million shs	630,567 shs
LOGC LogicBio Therapeutics	$12.84 +1.7%	$9.88	$7.05 ▼ $13.25	$587.19M	2.02	160,361 shs	54,304 shs
NBTX Nanobiotix	$41.23 -8.7%	$39.24	$8.03 ▼ $57.14	$2.09B	0.78	175,373 shs	164,856 shs
SRPT Sarepta Therapeutics	$20.86 -3.4%	$17.73	$14.68 ▼ $25.32	$2.20B	0.24	3.01 million shs	3.61 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	0.00%	-2.16%	+8.60%	+6.26%	+34.52%
LOGC LogicBio Therapeutics	0.00%	+13.23%	+33.75%	+42.98%	+72.35%
NBTX Nanobiotix	0.00%	-5.33%	+2.69%	+2.05%	+359.90%
SRPT Sarepta Therapeutics	0.00%	+11.02%	+34.06%	+16.73%	+15.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	2.67	Moderate Buy	$17.67	8.45% Upside
LOGC LogicBio Therapeutics	0.00	N/A	N/A	N/A
NBTX Nanobiotix	2.50	Moderate Buy	$37.33	-9.45% Downside
SRPT Sarepta Therapeutics	2.20	Hold	$25.06	20.13% Upside

Current Analyst Ratings Breakdown

Latest LOGC, NBTX, SRPT, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/20/2026	AUPH Aurinia Pharmaceuticals	Bloom Burton Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/19/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/12/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
8/12/2026	SRPT Sarepta Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$15.00 ➝ $16.00
8/5/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
7/28/2026	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/21/2026	AUPH Aurinia Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/20/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/17/2026	NBTX Nanobiotix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$283.05M	7.66	$1.01 per share	16.08	$4.41 per share	3.69
LOGC LogicBio Therapeutics	$10.16M	57.78	N/A	N/A	$4.95 per share	2.59
NBTX Nanobiotix	$36.87M	56.61	N/A	N/A	($1.97) per share	-20.93
SRPT Sarepta Therapeutics	$2.20B	1.00	N/A	N/A	$10.89 per share	1.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$287.20M	$2.29	7.11	18.94	N/A	100.84%	26.11%	19.89%	11/3/2026 (Estimated)
LOGC LogicBio Therapeutics	-$29M	-$0.73	N/A	N/A	N/A	N/A	-1.21%	-0.89%	11/3/2026 (Estimated)
NBTX Nanobiotix	-$27.11M	N/A	N/A	412.30	N/A	N/A	N/A	N/A	9/29/2026 (Estimated)
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	11.34	0.31	-13.48%	-1.60%	-0.66%	11/4/2026 (Estimated)

Latest LOGC, NBTX, SRPT, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	LOGC LogicBio Therapeutics	-$0.0414	-$0.14	-$0.0986	-$0.14	$33.60 million	$33.60 million
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LOGC LogicBio Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.07	5.42	4.97
LOGC LogicBio Therapeutics	0.29	1.87	1.24
NBTX Nanobiotix	N/A	1.09	1.09
SRPT Sarepta Therapeutics	0.55	4.42	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
LOGC LogicBio Therapeutics	46.05%
NBTX Nanobiotix	38.81%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	10.40%
LOGC LogicBio Therapeutics	42.47%
NBTX Nanobiotix	3.45%
SRPT Sarepta Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	133.05 million	119.21 million	Optionable
LOGC LogicBio Therapeutics	62	45.73 million	26.31 million	No Data
NBTX Nanobiotix	100	50.62 million	48.87 million	Not Optionable
SRPT Sarepta Therapeutics	1,372	105.63 million	98.34 million	Optionable

LOGC, NBTX, SRPT, and AUPH Headlines

Recent News About These Companies

Man Group plc Takes $7.16 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 30 at 5:11 AM | marketbeat.com

Freestone Grove Partners LP Acquires Shares of 76,629 Sarepta Therapeutics, Inc. $SRPT

August 30 at 3:59 AM | marketbeat.com

Jefferies Financial Group Inc. Takes $3.42 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 29 at 6:02 AM | marketbeat.com

Deutsche Bank AG Takes $2.04 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 29 at 4:04 AM | marketbeat.com

Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution

August 28 at 7:35 AM | seekingalpha.com

OMERS ADMINISTRATION Corp Takes $864,000 Position in Sarepta Therapeutics, Inc. $SRPT

August 28 at 5:12 AM | marketbeat.com

SRPT Poised for Biggest Rally in 5 Months as Late-2026 Clinical Data Sparks Retail Investors’ ‘Monumental Comeback’

August 27 at 7:59 PM | profitconfidential.comP

SRPT on track for best week in 5 months ahead of late-2026 clinical data — retail eyes monumental comeback

August 27 at 7:59 PM | msn.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 15.2% - What's Next?

August 27 at 1:39 PM | marketbeat.com

Ieq Capital LLC Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Takes $17.49 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

BlackRock Inc. Takes $341.34 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

August 24, 2026 | businesswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by Brokerages

August 24, 2026 | americanbankingnews.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of "Hold" by Brokerages

August 24, 2026 | marketbeat.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2% - Here's Why

August 19, 2026 | marketbeat.com

Sarepta Therapeutics Stock Short Interest Falls to 31.28%

August 18, 2026 | quiverquant.comQ

GSA Capital Partners LLP Purchases New Holdings in Sarepta Therapeutics, Inc. $SRPT

August 17, 2026 | marketbeat.com

Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research

August 14, 2026 | marketbeat.com

Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT

August 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LOGC, NBTX, SRPT, and AUPH Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$16.29 -0.19 (-1.15%)

As of 08/28/2026 04:00 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

LogicBio Therapeutics OTCMKTS:LOGC

$12.84 +0.22 (+1.74%)

As of 08/28/2026 03:57 PM Eastern

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Nanobiotix NASDAQ:NBTX

$41.23 -3.93 (-8.70%)

As of 08/28/2026 04:00 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Sarepta Therapeutics NASDAQ:SRPT

$20.86 -0.73 (-3.38%)

As of 08/28/2026 04:00 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LOGC, NBTX, SRPT, and AUPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LOGC, NBTX, SRPT, and AUPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LOGC, NBTX, SRPT, and AUPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LOGC, NBTX, SRPT, and AUPH Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

LogicBio Therapeutics OTCMKTS:LOGC

Nanobiotix NASDAQ:NBTX

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LOGC, NBTX, SRPT, and AUPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LOGC, NBTX, SRPT, and AUPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LOGC, NBTX, SRPT, and AUPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LOGC, NBTX, SRPT, and AUPH Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

LogicBio Therapeutics OTCMKTS:LOGC

Nanobiotix NASDAQ:NBTX

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools